Competitor Analysis: Malaria Vaccines & Therapeutics

Publisher: La Merie Publishing
Pages: 64
Format: PDF
Product Line:
Competitor Analysis
Product Code: LMCA0023
Release Date: August of 2012

300.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Malaria Vaccines

Product description

The present Competitive Intelligence Report about Malaria Vaccines & Therapeutics provides a competitor evaluation in the field of investigational small molecules and biologics to treat or prevent malaria and of vaccines against one or more antigens of the Plasmodium (Pl) parasite, especiall of Pl. falciparum, for prophylaxis of Malaria as of August 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Malaria is a mosquito-borne infectious disease caused by the Plasmodium parasite, especially Pl. falciparum. The parasite is transfected by the bite of a mosquito. Malaria is widespread in tropical and subtropical regions. Each year more than 350 million new cases of Malaria occur, it is one of the world’s most common diseases. People with malaria often experience fever, chills, and flu-like illness. Left untreated, they may develop severe complications and die. Non-profit organizations play a major role in supporting the discovery and development of novel vaccines to fight malaria. Industry partners are sought for production of the vaccine and to provide adjuvants if appropriate.

The report includes a compilation of currently active projects in development of small molecules and biologics as malaria therapeutics and of vaccines targeting antigens of the Plasmodium parasite for prophylaxis of Malaria. In addition, the report lists public and private company-specific R&D pipelines of Malaria Vaccines and Therapeutics. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Competitor Analysis: Malaria Vaccines and Therapeutics

Index

  • Malaria Vaccines
  • Biologics as Malaria Therapeutics
  • Small Molecule Malaria Therapeutics
  • Corporate and Public R&D Pipelines of Malaria Vaccines and Therapeutics
  • About La Merie



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top